Director of Drug Discovery
Salary commensurate with the seniority of the role.
The University of Sussex seeks to appoint an outstanding scientist to lead Drug Discovery within the Sussex Drug Discovery Centre.
Working closely with Academic Scientists within the Univerisity of Sussex, you will be responsible for leading a drug discovery capability with a view to producing molecules for innovative targets in diseases with unmet medical need.
We seek experienced drug-hunters with a proven track record of success in producing new molecular entities that have reached clinical development. Candidates will most likely be successful life scientists or medicinal chemists with experience in the pharma and biotech sector. The post-holder will have the vision to carry forward academic drug discovery at Sussex, combining industry experience with an academic mindset. We particularly encourage applications from those in the area of neuroscience and mental health disorders.
The Sussex Drug Discovery Centre was established in 2011 as an integral part of the School of Life Sciences within the main campus of Sussex University. The School of Life Sciences is the largest School in the University in terms of research activity, with an annual research turnover of £20M and 90 research and teaching faculty. It comprises research groupings in Neuroscience, Biochemistry and Biomedicine, Genome Damage and Stability, Evolution, Behaviour and Environment, Pharmacy and Chemistry. The research activities of the School of Life Sciences were ranked in the top 10 in REF2014.
An executive search is being carried out by Perrett Laver. To apply or to download further information on the required qualifications, skills and experience for the role, please visit www.perrettlaver.com/candidates quoting reference 3173.
Candidates who wish to discuss the role informally should contact Dr Ruth Murrell-Lagnado through Trudy Myers by telephone +44 (0)1273 872861, or via email T.Myers@sussex.ac.uk.
The closing date for applications is noon BST on Monday 8 October 2018.